Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib + Carboplatin vs Docetaxel + Carboplatin in Metastatic Castration-Resistant Prostate Cancer
NCT03517969Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started May 2019; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03517969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03517969.